You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors

    SBC: SignalRx Pharmaceuticals Inc.            Topic: NCI

    PARP inhibitors PARPi are particularly efficacious in tumors deficient in the BRCA tumor suppressor genes but of limited activity in BRCA competent tumors There is an unmet medical need to develop targeted therapeutic agents which will augment PARPi activity for BRCA wild type cancers and to increase chemo radiosensitivity in these malignancies BRCA proteins are essential components ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. The Effects of an Oral Nitric Oxide Lozenge on Peripheral Artery Disease

    SBC: Neogenis Laboratories, Inc.            Topic: 213

    Abstract Peripheral artery disease PAD is a common circulatory problem in which narrowed arteries reduce blood flow to your limbs thereby restricting blood flow During exercise or simply walking there is not sufficient blood flow to keep up with the metabolic demand This causes symptoms most notably leg pain when walking intermittent claudication PAD is also likely to be a sign of more w ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Whole Brain Nanoscale Preservation Imaging

    SBC: Nectome Inc.            Topic: 101

    Abstract Summary Nectome will create technologies to enable whole brain nanoscale preservation and imaging a vital step towards a deep understanding of the mind and of the brainandapos s diseases Current brain processing technologies compromise between whole brain applicability or nanoscale resolution our technologies will achieve both si multaneously Similar to the way that next generation ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. An Agent-Based Modeling Platform for Environmental Biotechnology

    SBC: MICROVI BIOTECH, INC.            Topic: NIEHS

    DESCRIPTION provided by applicant Hazardous compounds in waters and soils are subject to a complex dynamic web of interactions among physical chemical and biological constituents in the natural environment Computational modeling has been proven indispensable to hazardous substances remediation particularly integrated modeling of pollutant hydrogeological fate and transport For the first t ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Polymeric Percutaneous Pulmonary Valve for Use in Young Children

    SBC: Polyvascular Corp            Topic: NHLBI

    DESCRIPTION provided by applicant Congenital heart defects CHD represent the most common type of birth defect and are a leading cause of childhood deaths in the developed world Many forms of CHD require pulmonary valve PV replacement surgery which is typically performed with biologic valves such as human cadaveric donor valves which are in short supply Additionally such biologically ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. A small molecule integrin activator to enhance cord blood transplant

    SBC: 7 Hills Pharma LLC            Topic: NHLBI

    DESCRIPTION provided by applicant This proposal is in response to PA the parent announcement for STTR R grant applications Hematopoietic stem cell transplantation has become a preferred treatment for hematological malignancies and certain genetic disorders The use of umbilical cord blood cells as a source of hematopoietic stem cells for bone marrow transplantation has increased st ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Real Time Oxygen Monitoring for Tissue Health Peripheral Artery Disease Application

    SBC: PROFUSA, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Continuous biochemical monitoring has the power to change currently accepted standards of care shifting the emphasis from treating illness to maintaining health Point in time snapshots of a patientandapos s health can miss critical fluctuations or early warning signs that might warrant early interventions or changes in disease treatment and management PROFUS ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Peptide Based Therapy for Lung Fibrosis

    SBC: Novici Biotech LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately of deaths in developed countries whether idiopathic triggered by environmental factors infections or genetics organ fibrosis results in significant morbidity and mortality Organ fibrosis is responsible for health care costs exceeding $ billion year ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer.

    SBC: Acumen Pharmaceuticals, Inc            Topic: NIA

    In the United States in an estimated million people suffered from Alzheimer s disease AD with as many as being undiagnosed Alzheimer s Association Three stages of AD are proposed National Institute on Aging and the Alzheimer s Association preclinical AD mild cognitive impairment MCI due to AD and dementia due to AD The preclinical stage is proposed to begin ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Preclinical Evaluation of NCS-382 in Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD)

    SBC: SPERAGEN, INC.            Topic: 107

    SUMMARY Succinic semialdehyde dehydrogenase deficiency SSHDHD is an autosomal recessively inherited ultra rare disorder caused by accumulation of two neuromodulators in tissues and biofluids hydroxybutyrate GHB and aminobutyric acid GABA It is believed that the toxic action of GABA and GHB is mediated by their action on specific receptors widely distributed in the brain and other organ ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government